James West: Dr. Odidi, thank you for joining us today.
Dr. Isa Odidi: Thank you very much for having me, and thanks to all the listeners out there, all those who are looking at this online or through whatever medium. Thanks.
James West: Let’s start with an overview of what is the value proposition for investors in Intellipharmaceutics?
Dr. Isa Odidi: Basically, the (more…)
Intellipharmaceutics International (IPCI – Snapshot Report) announced that it has technologically upgraded its Rexista oxycodone development program to prevent overdose when tablets in excess of the prescribed dose are swallowed. Patents pending with the U.S. Patent and Trademark office cover the company’s new platform technology, PODRAS. The abuse-deterrent oxycodone is being developed to treat moderate-to-severe pain in situations requiring long-term use (more…)